EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID10600717

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID10600717


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	LLJNTLUXOZPFQB-UHFFFAOYSA-N
Smiles	Fc1ccc(cc1)C(=O)c1ccc(cc1)C(=O)c1ccc(F)cc1
InChI	InChI=1S/C20H12F2O2/c21-17-9-5-15(6-10-17)19(23)13-1-2-14(4-3-13)20(24)16-7-11-18(22)12-8-16/h1-12H

InChI Key

LLJNTLUXOZPFQB-UHFFFAOYSA-N

Smiles

Fc1ccc(cc1)C(=O)c1ccc(cc1)C(=O)c1ccc(F)cc1

InChI

InChI=1S/C20H12F2O2/c21-17-9-5-15(6-10-17)19(23)13-1-2-14(4-3-13)20(24)16-7-11-18(22)12-8-16/h1-12H

Property Name	Value
Molecular Formula	C20H12F2O2
Molecular Weight	322.08
AlogP	4.43
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	34.14
Molecular species	None
Aromatic Rings	3.0
Heavy Atoms	24.0

Property Name

Value

Molecular Formula

C20H12F2O2

Molecular Weight

322.08

AlogP

4.43

Hydrogen Bond Acceptor

2.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

4.0

Polar Surface Area

34.14

Molecular species

None

Aromatic Rings

3.0

Heavy Atoms

24.0

Resources	Reference
CAS NUMBER	68418-51-9
NORMAN SUSDAT
PubChem	11141804
ChemSpider	9316916.0

Resources

Reference

CAS NUMBER

68418-51-9

NORMAN SUSDAT

PubChem

11141804

ChemSpider

9316916.0


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

(1,4-DIFLUOROCYCLOHEXA-2,4-DIEN-1-YL)(PHENYL)METHANONE

Structure

Physicochemical Descriptors

Cross References